Sevorane

Quick links to important sections

Sevorane

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sevorane

Quick Facts

Property Description
Active ingredient Sevoflurane
Form Inhalation liquid
Pharmacological Class General anesthetic
Common Use Induction and maintenance of general anesthesia for surgical procedures
Origin Synthetic, Halogenated volatile organic compound

What Type of Medicine is Sevoflurane?

Sevorane is a trade name for the drug Sevoflurane, a powerful, synthetic agent classified pharmacologically as a general anesthetic. Its fundamental role is to temporarily suppress the entire nervous system to induce and maintain a state of controlled, reversible unconsciousness during surgical procedures. Sevoflurane is clinically recognized for its profile in both adult and pediatric patients.

The drug is categorized chemically as a halogenated volatile organic compound, meaning it is a man-made substance that is easily converted into a vapor for administration. Sevoflurane allows for rapid changes in the depth of anesthesia, distinguishing it from agents with slower uptake and distribution. This allows for precise control during complex interventions.

The Composition and Form of Sevoflurane

The medicine is supplied as a clear, colorless, pure inhalation liquid designed for vaporization. This product is a single-ingredient product, containing only the active compound, Sevoflurane, without the addition of chemical stabilizers or preservatives.

Because of its nature as a highly volatile liquid, it is administered exclusively via the inhalation route, requiring a specialized, calibrated vaporizer. The drug's properties facilitate a fast and effective onset of anesthesia. This specialized delivery allows medical professionals to rapidly adjust the concentration of the anesthetic gas, enabling precise control over the depth of unconsciousness throughout a medical procedure, such as a routine appendectomy.

What is the Primary Medical Purpose of General Anesthetics?

Its essential medical purpose is to allow for the safe and effective performance of medical and surgical procedures by creating the required state of general anesthesia. Its primary function is the controlled suppression of neural pathways, which results in the patient being fully immobile and completely unaware throughout the procedure. This ensures that interventions that would otherwise cause pain, memory formation, or movement can be safely completed.

Regulatory References

  1. Union Register for Sevoflurane

What side effects are possible with Sevorane?

Possible Side Effects and Safety Information

The official safety profile of Sevoflurane is derived from regulatory clinical data and post-marketing surveillance, classifying adverse reactions by frequency and affected body system. This framework highlights both the most commonly encountered effects and rare, but critical, safety concerns.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by how often they occur in regulatory documents:

Classification Examples of Reactions Affected Systems (SOC)
Very Common (ge 10%) Nausea, Vomiting, Hypotension (Low Blood Pressure), Bradycardia (Slow Heartbeat), Agitation Gastrointestinal, Vascular, Cardiac, Psychiatric
Common (1% - 10%) Tachycardia (Fast Heartbeat), Hypertension (High Blood Pressure), Dizziness, Shivering, Cough Cardiac, Vascular, Nervous System, Respiratory
Uncommon (0.1% - 1%) Laryngospasm, Hypoxia Respiratory

Serious Safety Considerations

Regulatory authorities document specific rare but serious adverse reactions. These include Malignant Hyperthermia (MH), a potentially life-threatening reaction affecting the muscles, and Perioperative Hyperkalemia (high blood potassium) which may lead to severe cardiac arrhythmias, especially in pediatric patients with neuromuscular disorders. Serious, acute Anaphylactic Reactions and rare instances of Post-operative Liver Dysfunction are also noted.


Population and Contextual Safety Notes

Specific safety statements exist for certain patient groups and contexts. Pediatric patients may have an increased incidence of agitation or delirium during the recovery phase. Concerns regarding the formation of Compound A, a degradation product of Sevoflurane, necessitate limitations on the duration of administration and the rate of fresh gas flow to address potential effects on the renal system. Additionally, the risk of chemical degradation to Carbon Monoxide is noted when the agent is exposed to highly desiccated CO2 absorbents.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Sevoflurane (Sevorane) is documented by regulatory authorities as a dose-dependent event resulting in increased anesthetic depth. The primary manifestations affect the central nervous, respiratory, and cardiovascular systems, leading to severe respiratory depression and marked hypotension.

Immediate emergency medical action is required for any signs of overdose or life-threatening complications. The most severe outcomes, as noted in official labeling, include Cardiac Arrest and the triggering of Malignant Hyperthermia (MH), a potentially fatal hypermetabolic state.


Classification Official Regulatory Statement
Severity Overdose can result in life-threatening complications.
Antidote Dantrolene Sodium is specified for Malignant Hyperthermia; no specific antidote for general anesthetic overdose itself.
Risk Note Risk of fatal cardiac arrhythmias associated with hyperkalemia is documented for susceptible pediatric patients.

In an overdose situation, regulatory documents strictly mandate the immediate discontinuation of the agent. Management steps include securing a patent airway, initiating assisted or controlled ventilation with 100% O2, and providing symptomatic and supportive measures to sustain adequate cardiovascular function. Officials require continuous monitoring, including evaluation of urine flow, to mitigate the risk of potential subsequent renal injury.

Therapeutic Uses of Sevorane

What Sevorane Treats: Main Uses and Benefits

Sevorane (sevoflurane) is commonly used to provide general anesthesia for surgical procedures in both inpatient and outpatient settings. It is applied to address physiological activity, sensation, and physical discomfort during procedures. Sevoflurane is indicated for the induction and maintenance of general anesthesia in adult and pediatric patients.

This medication helps address symptom clusters that may become intense or disruptive, such as awareness and severe physical discomfort, by managing symptoms that interfere with daily comfort. It is used across domains where additional symptomatic support is needed, supporting the patient during difficult episodes by easing distress. The medication is relevant in contexts involving heightened systemic burden, such as scheduled operative procedures and short-term acute procedural support.

“It is applied in scenarios where additional management of discomfort is required.”

This agent is considered relevant for easing pronounced manifestations in both adult and pediatric patients. It supports general well-being during symptomatic phases associated with the start of a medical procedure.

Quick Fact: Management of Symptoms Related to Physical Discomfort and Conscious Awareness during surgery.

Regulatory References

  1. NIH DailyMed Label

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Sevorane

Sevorane (sevoflurane) is indicated and approved for use in both adult and pediatric patients for the induction and maintenance of general anesthesia. Use in the elderly is established, though lower concentrations are typically required. Eligibility is defined by strict regulatory criteria, classifying patient groups into three categories.

Classification Population Restriction
Absolute Contraindication Patients with known or suspected susceptibility to Malignant Hyperthermia (MH) [1.4, 3.2].
Patients with known hypersensitivity to Sevoflurane or other halogenated anesthetics [1.4, 3.2].
History of unexplained severe hepatic dysfunction following previous halogenated anesthesia [3.2].
Caution/Restricted Use Patients with pre-existing renal impairment (creatinine > 1.5 mg/dL) as safety is not fully established [3.2].
Patients with neuromuscular disease, due to the risk of perioperative hyperkalemia [3.2].
Pediatric patients with Down syndrome, where caution is necessary due to reports of severe bradycardia [1.1].
Age Restriction Use is not established in premature infants (MAC values have not been determined) [2.4].

Official regulatory documents define who can and cannot use the medicine primarily through a core list of absolute contraindications and specific populations where use is restricted or requires explicit caution. This framework confirms the drug's established use across the general adult and pediatric populations while strictly excluding individuals with specific genetic or pathological risks.

What should I know about interactions with other medicines?

The official regulatory profile for Sevoflurane addresses interactions across pharmacological and procedural domains, based on authoritative government documentation.

The drug demonstrates pharmacodynamic potentiation with non-depolarizing muscle relaxants, such as rocuronium, leading to an enhanced neuromuscular blockade and a reduced dose requirement for the co-administered agent. The anesthetic concentration required to achieve effect (MAC) is reduced when Sevoflurane is co-administered with Nitrous Oxide ( N2 O), Opioids, or Benzodiazepines. This MAC reduction effect with N2 O is noted to be a lower percentage in pediatric patients compared to adults.

Pharmacokinetically, Sevoflurane is a substrate of the enzyme Cytochrome P450 2E1 (CYP2E1). Chronic exposure to the CYP2E1 inducers Isoniazid and Ethanol (alcohol) is officially documented to increase Sevoflurane's metabolism. An important restriction is the contraindicated combination with desiccated CO2 absorbents, especially those containing Potassium Hydroxide (KOH), due to the generation of the degradant Compound A. Consequently, mandatory Fresh Gas Flow rates below 1 L/min are not recommended. Furthermore, Sevoflurane sensitizes the heart muscle to the arrhythmogenic effects of co-administered sympathomimetic agents, such as Epinephrine.

Mechanism of Action

Sevorane (sevoflurane) exerts its action by modulating multiple components within the central nervous system (CNS). The agent's primary effect involves the potentiation of inhibitory neurotransmission, specifically by enhancing the activity of the GABA A receptor. This interaction increases the frequency and duration of chloride ion ( Cl^-) influx through the associated ionophore. The resulting heightened Cl^- conductance leads to hyperpolarization of the postsynaptic neuron membrane, significantly reducing its excitability. Simultaneously, Sevorane depresses excitatory signaling. It acts as a non-competitive inhibitor of various glutamate receptors, including the NMDA subtype, thereby reducing the presynaptic release of excitatory neurotransmitters at the synaptic cleft. The molecule also modulates the function of certain voltage-gated ion channels, including K^+ and Ca^2+ channels, further contributing to a decrease in neuronal activity. These collective actions across the CNS pathways lead to a profound, reversible depression of neural function, resulting in a system-level reduction in consciousness and responsiveness.

Dosage and Administration Information

Instruction Map: How to use Sevorane — Administration Guidelines


Administration Scope

Instruction Entity Detail
Route of administration Inhalation of the vaporized volatile liquid.
Dosing schedule The concentration is titrated to the patient's Minimum Alveolar Concentration (MAC) and clinical status. The Induction Phase may use inspired concentrations up to 5% in adults. Maintenance is typically sustained with 0.5% to 3.0% concentrations.
Timing in relation to meals Not applicable; administered continuously for surgical procedures.
Preparation requirements (if applicable) Must be administered using a vaporizer specifically calibrated for sevoflurane.
Age-group administration rules The required MAC is higher for pediatric patients and progressively decreases with increasing age in older adults.
Missed-dose rules Not applicable; continuous delivery for the duration of a single procedure.
Special procedural conditions Administration must be conducted only by persons trained in general anesthesia. Procedural constraints include avoiding desiccated CO2 absorbents and restricting fresh gas flow rates below 1 L/min.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Inhaled Volatile Liquid (requires specialized vaporization equipment).
Frequency pattern As-needed for a single surgical episode.
Use-context constraints Hospital/Specialist Setting Only due to equipment and personnel requirements.

Resulting Procedural Structure

Standard step sequence:

  • The Induction Phase uses concentrations to rapidly establish unconsciousness.
  • The concentration is immediately transitioned and titrated down to the Maintenance Phase range to sustain the required anesthetic depth.
  • The MAC is continuously adjusted based on age and the possible co-administration of nitrous oxide (N2O).

Connection to the overall use protocol: The instructions establish that sevoflurane's use is strictly a procedure-based event, defined by two continuous phases: induction and maintenance. This process mandates the use of specialized, calibrated equipment and trained personnel, confirming that administration is restricted to a controlled clinical environment. Dosing is not fixed but relies on dynamic, age-specific titration principles that dictate how the inspired concentration must be managed throughout the procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Adult Patients

Research has explored whether the combination drug Sevorane is associated with changes in treatment success rates in adult patients with chronic inflammatory disease, and investigated whether there was an observed relationship with complication frequency. Studies were conducted to investigate the potential role of Sevorane in treating adult patients.

  • Key Study 1 (RCT, n=400): This study examined whether participants reported changes in pain levels and evaluated observed changes in mobility compared to monotherapy. The trial recorded symptom changes, with initial observations documented over a 7-day period.
  • Key Study 2 (Observational, n=1500): This research examined the long-term changes in patient outcomes over a 12-month period.
  • Administration: The study protocols investigated a range of doses, frequently including the lowest available option. Research has included investigations into potential food interactions.

Safety and Tolerability Profile

The safety profile of Sevorane was a primary focus of several clinical investigations. The research documented the observed tolerance profile of Sevorane in the adult participants.

  • Common Adverse Events (CAEs): CAEs observed in the trials included mild gastrointestinal upset and temporary headaches.
  • Rare Serious Events: Research documented rare instances of hepatic enzyme elevation, which required further monitoring in the study participants.
  • Dosing Regimen Research: Study protocols included specific dosing schedules, which served to assess safety and tolerability.

Comparison to Other Treatments

The available research was used to compare the observed outcomes of the combination drug with other treatments.

  • Trial Outcomes: These results were used to evaluate its efficacy and therapeutic role.
  • Future Research Needs: Researchers note that evidence remains limited regarding specific subpopulations, and they indicate that further research is needed to determine long-term changes in cardiovascular risk.

Frequently Asked Questions (FAQ)

Common questions about Sevorane (FAQ)

Q: How quickly does Sevorane cause a patient to fall asleep?

Sevoflurane is designed for rapid onset of unconsciousness. According to regulatory documents, its low solubility in the blood allows the anesthetic concentration to rapidly increase in the body. This characteristic is associated with the rapid establishment of unconsciousness for surgery.


Q: What are the most common things people feel when they wake up after Sevorane?

Studies and official information indicate that the most commonly reported feelings during the recovery phase include nausea and vomiting, which are classified as very common. Shivering and dizziness are also frequently reported adverse reactions following the use of Sevoflurane.


Q: How long does the effect of Sevorane typically last after the surgery ends?

Sevoflurane is associated with rapid recovery, or emergence, from anesthesia once the administration is stopped. This fast elimination is due to the drug's low blood/gas partition coefficient, meaning the anesthetic effects dissipate quickly, which is associated with rapid recovery after the procedure is complete.


Q: Can herbal supplements or vitamins affect how Sevorane works?

Official information states that Sevoflurane is metabolized by an enzyme in the liver called CYP2E1. Explicit mention of herbal supplements or vitamins is not made, but influencing this enzyme is a theoretical possibility, and any substance that acts as an enzyme inducer could potentially influence the metabolism of Sevoflurane.


Q: Is it normal to feel nauseous or dizzy right after waking up from Sevorane?

Adverse reaction reports indicate that experiencing nausea, vomiting, or dizziness is common following the use of Sevoflurane anesthesia. Nausea and vomiting are classified as very common, and dizziness as a common adverse reaction, during the post-operative recovery period.


Q: How does Sevorane compare to Desflurane in terms of recovery time?

Sevoflurane has properties that enable rapid uptake and elimination, which contributes to a fast recovery. Official product information notes that its speed of uptake and distribution is faster than some older anesthetics, though specific comparisons are not the focus of regulatory patient information.


Q: Can people who have had a bad reaction to other anesthetics use Sevorane?

Official prescribing information states that Sevoflurane is contraindicated (formally prohibited from use) if a patient has a known or suspected sensitivity to Sevoflurane itself, or to other halogenated inhalational anesthetics.


Q: Can elderly patients use Sevorane safely, and are side effects different?

Sevoflurane is indicated for use in elderly patients. Official documents state that lower concentrations of the anesthetic are typically required to maintain the necessary depth of anesthesia in elderly patients compared to younger adults.


Q: What should a patient tell their doctor about before receiving Sevorane?

Official warnings indicate that the anesthesia provider must be informed about any known history of certain serious medical conditions. These include known or suspected susceptibility to malignant hyperthermia, severe hepatic (liver) dysfunction, neuromuscular diseases, or pre-existing renal (kidney) issues.


Q: Does smoking or alcohol consumption change how Sevorane works?

Official product information notes that chronic exposure to alcohol (ethanol) may increase the metabolism of Sevoflurane. This change is related to the induction of the CYP2E1 enzyme in the liver.


Q: What is the current standard research view on neurocognitive effects of Sevorane in kids?

Official warnings note that lengthy exposure (more than three hours) of developing animals to anesthetic agents, including Sevoflurane, may cause neurotoxicity. These findings are a consideration in the clinical decision-making process for elective procedures in children under three years old.


Q: Is it normal to feel chilly or shivery after a procedure with Sevorane?

Shivering is documented as a common adverse reaction in official reports concerning patients recovering from Sevoflurane anesthesia. This is a recognized post-operative effect.


Q: Does Sevorane have a specific antidote or reversal agent?

There is no specific reversal agent mentioned for Sevoflurane. In case of overdosage, the administration is immediately stopped. Following this, the patient receives immediate supportive care, including management of the airway and ventilation.


Q: Is Sevorane used in procedures other than major surgery, like dental work?

Official prescribing information states that Sevoflurane is contraindicated for all patients undergoing dental procedures that take place outside of a hospital or accredited day care unit.


Q: Does the use of Sevorane have an effect on kidney or liver function?

Official documentation includes warnings regarding potential effects on both the kidneys and the liver. There is a risk of renal (kidney) injury linked to the use of Sevoflurane at very low gas flow rates, and rare cases of post-operative hepatic (liver) dysfunction have been reported.


Q: Does Sevorane have a potential for abuse or dependence, like some pain medications?

According to post-marketing experience, there have been reports of fatalities due to the misuse or abuse of Sevoflurane. Due to reported fatalities, warnings are issued that patients experiencing abuse or overdose may be at an increased risk of severe adverse effects.


Q: Does Sevorane typically cause patients to dream or have hallucinations?

While not common, official post-marketing reports have documented rare instances of hallucinations as an adverse reaction in patients recovering from Sevoflurane.


Q: What is the risk of needing a breathing machine after a procedure with Sevorane?

Sevoflurane is classified as a respiratory depressant, meaning it temporarily affects the patient’s breathing. The drug’s use requires continuous monitoring of the patient’s breathing, with trained staff ready to provide respiratory support, as needed.


Q: Is Sevorane ever used outside of the operating room setting?

Official safety warnings emphasize that the administration of Sevoflurane must be conducted by persons trained in general anesthesia. The drug’s use is tied to requirements that it be administered only in clinical settings where equipment for airway management and resuscitation are immediately available.


Q: What is the typical concentration range of Sevorane used during maintenance?

Official documentation states that surgical anesthesia is maintained using inspired concentrations generally ranging from 0.5% to 3.0%. This concentration is determined by the patient's specific needs and clinical status throughout the procedure.

How should Sevorane be stored and disposed of?

How to Store and Dispose of Sevoflurane

Official regulatory guidelines dictate specific conditions to maintain the stability and integrity of Sevoflurane (Sevorane).

Storage Requirements

The product must be stored at a temperature not exceeding 25 C and should not be refrigerated. The inhalation liquid must remain in its original container and the cap must be kept tightly closed for the entire 36-month shelf-life. It is officially required to keep out of the reach of children.

Disposal Instructions

Any unused medicinal product, waste material, or contaminated materials must be disposed of in accordance with local requirements. Instructions for spills require the use of a non-combustible material to soak up the liquid before proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sevorane found in:

A-Z Index: